Qingdao Vland Biotech Co Ltd Total Liabilities
Qingdao Vland Biotech Co Ltd total liabilities. Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) has total liabilities worth CN¥1.14 Billion CNY (≈ $166.87 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 603739 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Qingdao Vland Biotech Co Ltd (2014–2024)
Total liabilities of Qingdao Vland Biotech Co Ltd from 2014 to 2024. This chart illustrates how Qingdao Vland Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Qingdao Vland Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Qingdao Vland Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Magnera Corp placeholder
NYSE:MAGN
|
USA | $2.82 Billion |
|
Ovzon AB
ST:OVZON
|
Sweden | Skr663.00 Million |
|
Lafang China
SHG:603630
|
China | CN¥257.81 Million |
|
HaiXin Foods Co Ltd
SHE:002702
|
China | CN¥893.49 Million |
|
Kolte - Patil Developers Limited
NSE:KOLTEPATIL
|
India | Rs-12.05 Billion |
|
Shanghai HIUV New Materials Co Ltd
SHG:688680
|
China | CN¥1.48 Billion |
|
CW Enerji SA
IS:CWENE
|
Turkey | TL20.29 Billion |
|
Shyft Group Inc
NASDAQ:SHYF
|
USA | $333.76 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Qingdao Vland Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Qingdao Vland Biotech Co Ltd.
Liquidity & Leverage Metrics
Qingdao Vland Biotech Co Ltd Total Liabilities Ratios Explained
Qingdao Vland Biotech Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qingdao Vland Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below shows the annual total liabilities of Qingdao Vland Biotech Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.11 Billion ≈ $162.57 Million |
-8.08% |
| 2023-12-31 | CN¥1.21 Billion ≈ $176.87 Million |
+43.05% |
| 2022-12-31 | CN¥844.93 Million ≈ $123.64 Million |
+57.59% |
| 2021-12-31 | CN¥536.18 Million ≈ $78.46 Million |
+59.47% |
| 2020-12-31 | CN¥336.22 Million ≈ $49.20 Million |
+35.03% |
| 2019-12-31 | CN¥248.99 Million ≈ $36.44 Million |
-20.69% |
| 2018-12-31 | CN¥313.94 Million ≈ $45.94 Million |
+7.88% |
| 2017-12-31 | CN¥291.02 Million ≈ $42.59 Million |
+7.80% |
| 2016-12-31 | CN¥269.96 Million ≈ $39.50 Million |
-10.69% |
| 2015-12-31 | CN¥302.27 Million ≈ $44.23 Million |
-8.00% |
| 2014-12-31 | CN¥328.53 Million ≈ $48.07 Million |
-- |
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more